You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • M30 Effect of dose reductions and/or interruptions on the efficacy of nintedanib in patients with idiopathic pulmonary fibrosis (ipf): subgroup analysis of the inpulsis trials

Article Text

Article menu

Download PDFPDF

Declarations of Interest
M30 Effect of dose reductions and/or interruptions on the efficacy of nintedanib in patients with idiopathic pulmonary fibrosis (ipf): subgroup analysis of the inpulsis trials
Free

Abstract

T Maher reports that he is an investigator in an ongoing phase 2b study from Gilead, grants and personal fees from GSK, grants from Novartis, personal fees from Boehringer Ingelheim, personal fees from GSK, personal fees from InterMune, personal fees from Lanthio, non-financial support from Takeda, personal fees from Sanofi Aventis, grants and non-financial support from UCB, personal fees from Astra Zeneca, personal fees from Roche, personal fees from Bayer, personal fees from Biogen Idec, personal fees from Cipla, personal fees from DOSA, personal fees from ProMetic, personal fees from Galapagos, outside the submitted work.

Y Inoue personal fees from Boehringer Ingelheim, personal fees from Shionogi & Co., Ltd, personal fees from Asahi Kasei, personal fees from Novartis, personal fees from Nobel Pharma, outside the submitted work.

AH Case reports personal fees from Boehringer Ingelheim, outside the submitted work.

W Sakamoto and S Stowasser are employees of Boehringer Ingelheim.

WA Wuyts reports grants from Boehringer Ingelheim, grants from Roche, outside the submitted work.

https://doi.org/10.1136/thoraxjnl-2017-210983.476

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.